Gardasil

/ MSD

The usually recommended vaccination schedule is:
If you are from 9 to and including 13 years of age: GARDASIL can be administered according to a 2-dose schedule:
– First injection: at chosen date
– Second injection: 6 months after first injection
If the second vaccine dose is administered earlier than 6 months after the first dose, a third dose should always be administered.
Alternatively, GARDASIL can be administered according to a 3-dose schedule:
– First injection: at chosen date
– Second injection: 2 months after first injection
– Third injection: 6 months after first injection
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period. Please speak to your doctor for more information.
If you are from 14 years of age: GARDASIL should be administered according to a 3-dose schedule:
– First injection: at chosen date
– Second injection: 2 months after first injection
– Third injection: 6 months after first injection
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period. Please speak to your doctor for more information.
It is recommended that individuals who receive a first dose of GARDASIL complete the vaccination course with GARDASIL.
The vaccine should not be mixed in the same syringe with any other vaccines and solutions.

For females aged 9 through 45 years, for the prevention of cervical, vulvar, and vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18 (which are included in the vaccine). For males aged 9 through 15 years for the prevention of infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18 (which are included in the vaccine).Immunogenicity studies have been conducted to link efficacy in females aged 16 to 26 years to the younger populations.

Hypersensitivity to the active substances or to any of the excipients of the vaccine. Individuals who develop symptoms indicative of hypersensitivity after receiving a dose of the vaccine should not receive further doses.

As for any vaccine, vaccination may not result in protection in all vaccine recipients. Not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN or VaIN.
Pregnancy and lactation: Should be given during pregnancy only if clearly needed. Caution should be exercised when administered to a nursing woman.

Mild pain, swelling, erythema.

May be administered simultaneously with other vaccines or immunoglobulins provided two different injection sites are used, as well as different syringes.